Previous 10 | Next 10 |
Gainers: Blue Water Vaccines ( BWV ) +57% . Eargo ( EAR ) +49% . Cassava Sciences ( SAVA ) +29% . MiNK Therapeutics ( INKT ) +24% . Cogent Biosciences ( COGT ) +16% . Losers: Blueprint Medicines ( BPMC ) -22% ....
Blueprint Medicines ( BPMC ) -13% on reports to seek label expansion for systemic mastocytosis therapy after trial win . Artelo Biosciences ( ARTL ) -13% . Krispy Kreme ( DNUT ) -12% on Q2 earnings release . Forza X1 ( FRZA ) -12% . ...
Gainers: GreenBox ( GBOX ) +107% . Bed Bath & Beyond ( BBBY ) +55% . Artelo Biosciences ( ARTL ) +49% . Kirkland's ( KIRK ) +44% . SkyWater Technology ( SKYT ) +37% . fuboTV ( FUBO ) +33% . Ventyx Biosciences ...
Gainers: Artelo Biosciences ( ARTL ) +31% . Ventyx Biosciences ( VTYX ) +23% . Eargo ( EAR ) +19% . Fulcrum Therapeutics ( FULC ) +18% . Genprex ( GNPX ) +17% . Losers: Albireo Pharma ( ALBO ) -25% . Sema4...
Nano-cap stock Artelo Biosciences ( NASDAQ: ARTL ) added ~21% in the morning hours Tuesday after the clinical-stage pharma announced the recent publication of pre-clinical data supporting the potential of its FABP inhibitor therapeutic platform in anxiety-related disorders...
SOLANA BEACH, Calif., Aug. 16, 2022 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) , a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, and neurological conditions, t...
AMTD IDEA ( AMTD ) +38% Group to Inject US$500 Million Worth of Global Portfolio of Premium Real Estate Assets Located in Major Cities into AMTD Digital Inc. Ginkgo Bioworks Holdings ( DNA ) +22% . Zymergen ( ZY ) +20% Q2 earnings release . Gree...
Artelo Biosciences press release ( NASDAQ: ARTL ): Q2 GAAP EPS of -$0.87. As of June 30, 2022, the Company had approximately $21.3 million in cash and investments, compared to $25.6 million as of December 31, 2021. Shares -5.76% PM. For further details see: ...
CAReS Study Evaluating ART27.13 in Cancer Anorexia Progresses to Fourth Cohort ART26.12 Program to Target Chemotherapy-Induced Peripheral Neuropathy $21.3 Million in Cash and Investments as of June 30, 2022 15-for-1 Reverse Stock Split to be Effective August 10, 20...
SOLANA BEACH, Calif., July 19, 2022 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. ( Nasdaq: ARTL ), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, and neurological conditions, toda...
News, Short Squeeze, Breakout and More Instantly...
Artelo Biosciences Inc. Company Name:
ARTL Stock Symbol:
OTCMKTS Market:
Artelo Biosciences Inc. Website:
SOLANA BEACH, Calif., July 03, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) , a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatologic and neurological condit...
Inhibition of FABP5 Demonstrates Activity in Cancer, Psoriasis, and Anxiety Disorders Results from Several Research Studies Presented at the Annual ICRS Symposium SOLANA BEACH, Calif., July 02, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) , a c...
SOLANA BEACH, Calif., July 01, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) , a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatologic and neurological condit...